血溶性 ангиотензин转化酶2和再次中风的风险:一个嵌套的病例控制分析
Jing Xue1,2,3, Mingming Shi4,5,6, Qin Xu4,5
1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, xuejing062@163.com.
Cerebrovascular diseases (Basel, Switzerland)
|March 12, 2024
概括
溶性血管激素转化酶2 (sACE-2) 的升高水平与复发性中风的更高风险有关. 这一发现在患有较高系统性炎症的患者中尤为明显,这表明SACE-2是中风复发的潜在生物标志物.
科学领域:
- 心血管研究研究心血管研究
- 神经学 神经学
- 生物标志物发现发现
背景情况:
- 溶解性血管激素转化酶2 (sACE-2) 与不良的心血管结果有关.
- sACE-2和中风复发之间的联系仍然不清楚.
- 这项研究调查了在患有缺血性中风或短暂缺血性发作的患者中sACE-2水平和复发性中风之间的关系.
研究的目的:
- 确定血SACE-2度与一年内中风复发风险之间的关联.
- 探索系统性炎症是否会改变sACE-2和中风复发之间的关系.
主要方法:
- 通过第三中国国家中风注册局 (CNSR-III) 的数据进行了一项病例控制研究.
- 分析了988名患者 (494例复发性中风病例和494例匹配对照).
- 条件后勤回归模型被用来评估sACE-2水平和复发性中风之间的关联.
主要成果:
- 中位数SACE-2水平为25.17 ng/mL.
- 在调整了混因素后,SACE-2的最高四分位数与复发性中风风险增加1.68倍有关 (OR: 1.68,95% CI: 1.12-2.53).
- 亚组分析显示,高敏感性C反应蛋白≥2 mg/L或中性粒细胞数≥中位数的患者中,SACE-2升高和中风复发之间存在显著的关联,这表明系统性炎症的作用.
结论:
- 血SACE-2度升高与复发性中风风险增加显著相关.
- 系统性炎症可能会增加高SACE-2水平的个体中风复发的风险.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
625
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
625
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
636
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
636
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
730
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
730
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126